[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management",
    "summary": "Amgen (AMGN) recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings growth, with Q2 revenue rising to $9,179 million. Despite a 3% price increase over the last quarter, the overall market showed a 15% annual growth trend, which suggests that Amgen’s developments in expanding product approvals and strong earnings may have contributed positively, aligning...",
    "url": "https://finnhub.io/api/news?id=3f16ae9093e0b94294b4e66cc969703c825c0087787e3d2b7286eb15d7f327b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756229211,
      "headline": "Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management",
      "id": 136530232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings growth, with Q2 revenue rising to $9,179 million. Despite a 3% price increase over the last quarter, the overall market showed a 15% annual growth trend, which suggests that Amgen’s developments in expanding product approvals and strong earnings may have contributed positively, aligning...",
      "url": "https://finnhub.io/api/news?id=3f16ae9093e0b94294b4e66cc969703c825c0087787e3d2b7286eb15d7f327b0"
    }
  },
  {
    "ts": null,
    "headline": "AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?",
    "summary": "Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.",
    "url": "https://finnhub.io/api/news?id=e9ae8a21897dd2166cd562557d9563a61343fc542a64763b6d02bc6364ea107b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756209960,
      "headline": "AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?",
      "id": 136525067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.",
      "url": "https://finnhub.io/api/news?id=e9ae8a21897dd2166cd562557d9563a61343fc542a64763b6d02bc6364ea107b"
    }
  }
]